TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02734342

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: Participants will be asked to attend eight exercise sessions within a group class environment that will last for 1 hour. The exercise programme has been developed through clinical and research evidence. During the hour, a 5 minute warm up followed by 14 exercises specific to strengthening the lower limb and improving aerobic capacity. Each exercise will be timed for two minutes with the participant reporting number of repetitions counted. A cool down will be completed at the end of the class. After each exercise class, the participant will be advised to have a recovery day to prevent overloading (De Carlo \& Armstrong, 2010). Progression of exercises will be patient led. Participants will attend twice per week for four weeks.
Study: NCT04052672

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise and Nutritional Supplement
Description: The intervention consists of exercise (a combination of supervised and in home) as well as a nutritional supplement (a combination of whey protein and creatine).
Study: NCT01815268

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HD Vaccine
Description: Nursing home residents over 65 years are allocated to receive high-dose vaccine. Residents under 65 years are provided standard-dose vaccine.
Study: NCT02286518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-114 10 mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-114 10 mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-114 10 mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-114 10 mg capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TAK-114 matched placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TAK-114 matched placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TAK-114 matched placebo
Study: NCT02818283

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Soy Pretzel
Description: Each packet (5oz.) of soy pretzel contains high gluten wheat flour, soy flour, soymilk, vegetable shortening, sugar, yeast, salt, and ascorbic acid. Each packet provides \~280 calories (16% fat, 54% total carbohydrates, and 30% protein).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soy Pretzel
Description: Each packet (5oz.) of soy pretzel contains high gluten wheat flour, soy flour, soymilk, vegetable shortening, sugar, yeast, salt, and ascorbic acid. Each packet provides \~280 calories (16% fat, 54% total carbohydrates, and 30% protein).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Wheat Pretzel
Description: Each packet (5oz.) of wheat pretzel contains high gluten wheat flour, vital wheat gluten, shortening, sugar, yeast, salt, and ascorbic acid. Each packet provides \~290 calories (16% fat, 54% total carbohydrates, and 30% protein).
Study: NCT01859325

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rVSV
Description: Attenuated recombinant vesicular stomatitis virus containing HIV-1 gag gene

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL-12 pDNA adjuvant
Description: plasmid DNA containing human IL-12 gene

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HIV-Mag pDNA
Description: plasmid DNA vaccine containing genes encoding multiple HIV-1 proteins

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01566799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: metformin 500 mg/day po for 24 weeks.
Study: NCT02981797

Intervention type: OTHER
Intervention: Blood Collection During Standard of Care Treatment
Description: Blood collection for baseline CTC numeration and H2AX assay. Circulating prostate cancer cell analysis requires blood draw of 7.5 ml (about 1 ½ teaspoons) of blood, to be performed at the screening, 1-2 hours before the third and sixth dose of radium 223 and 24 hours after the first, third, sixth dose of Radium 223. Standard of care Radium 223 treatment is given every 4 weeks for a total of 6 treatments and post Radium 223 follow up at week 24 is also considered standard of care. Other than these standard clinic visits and treatments, the study only requires 3 extra trips to the cancer center for blood draw at 24 hours after the first, third, sixth dose of Radium 223. Blood draws other than circulating tumor cell analysis is considered standard of care and doesn't require extra visits.
Study: NCT01178983

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: surface electromyography
Description: Surface electromyography (SEMG) telebiofeedback

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: surface electromyography
Description: conventional biofeedback
Study: NCT04376723

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mental Health Mobile Application
Description: Mobile phones will not be provided to participants, but app subscriptions will be provided.
Study: NCT00190307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin 75 mg/day
Description: aspirin 75 mg/day
Study: NCT01815268

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HD Vaccine
Description: Nursing home residents over 65 years are allocated to receive high-dose vaccine. Residents under 65 years are provided standard-dose vaccine.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: SD Vaccine
Description: Nursing home residents are allocated to receive standard-dose vaccine.
Study: NCT02179892

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV Acetaminophen
Description: Intravenous (IV) acetaminophen 1000 mg every 8 hours for 8 doses.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV Acetaminophen
Description: Intravenous (IV) acetaminophen 1000 mg every 8 hours for 8 doses.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Acetaminophen
Description: Oral acetaminophen 650 mg every 6 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Acetaminophen
Description: Oral acetaminophen 650 mg every 6 hours.
Study: NCT04513444

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Relaxation with music listening and medical hypnosis during radiotherapy treatment:
Description: * Music listening (According to the patient's wishes),~* Hypnosis sessions with the hypnotherapist during the 1st, 2nd and 3rd radiotherapy session,~* Self-hypnosis during the 4th and 5th radiotherapy session,~* Questionnaires (STAI-Y and QLQ-C30) and numerical scales (anxiety and pain) will be completed by patients during radiotherapy consultations.

Intervention type: OTHER
Group type: OTHER
Intervention: Relaxation with music listening during radiotherapy treatment:
Description: * Music listening (According to the patient's wishes),~* Questionnaires (STAI-Y and QLQ-C30) and numerical scales (anxiety and pain) will be completed by patients during radiotherapy consultations.
Study: NCT04968535

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: StimaWELL
Description: mid frequent electrotherapy mat covering the whole spinal cord with different stimulation protocols installed

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: StimaWELL
Description: mid frequent electrotherapy mat covering the whole spinal cord with different stimulation protocols installed
Study: NCT00256412

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eicosapentaenoic acid (EPA) 0.7 grams/day or 1.5 grams/day
Description: Placebo and Omega 3 capsules. All participants receive 4 capsules with either 0, 2, or 4 capsules containing omega 3.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eicosapentaenoic acid (EPA) 0.7 grams/day or 1.5 grams/day
Description: Placebo and Omega 3 capsules. All participants receive 4 capsules with either 0, 2, or 4 capsules containing omega 3.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 capsules of placebo each day
Study: NCT01027520

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: application of coban dressing
Description: application of a intraoperative coban dressing with reapplications following dressing removal.
Study: NCT03798028

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UC-MSCs
Description: The UC-MSCs will be administrated by intravenous injection at the dose of 1×10\^6 cells/kg.
Study: NCT02830503

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Feeding tube daily replacement
Description: Feeding tubes replaced once a day in the first week of life.
Study: NCT02119403

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: There are no other inteventions.
Description: This device gives patients the opportunity to receive nitrous oxide where no such opportunity exists. There is no other intervention available that creates immediate short term minimal sedation.
Study: NCT02104674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lebrikizumab
Description: Given SC on Days 1, 29, and 57

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: montelukast [Singulair]
Description: 10 mg given orally once daily for 12 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: SC injection given on Days 1, 29, and 57
Study: NCT05030883

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Source of news
Description: The main intervention was the source of the news that was shown to participants

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Source of news
Description: The main intervention was the source of the news that was shown to participants

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Source of news
Description: The main intervention was the source of the news that was shown to participants
Study: NCT01961219

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manipulation Under Anesthesia
Description: Closed manipulation under anesthesia.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopic capsular release
Description: Arthroscopic capsular release
Study: NCT03806114

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Posterior Approach Precautions
Description: These patients will be advised not to bend their leg or trunk more than 90 degrees, avoid crossing the leg or crossing midline, and rotating the leg inwards. Patients will also be instructed to put a pillow in between their legs while sleeping for 6 weeks and to avoid bathing for 6 weeks.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Anterior Approach Precautions
Description: These patients will be advised to avoid extending the leg back, rotating the leg outwards, and lifting their bottom when lying down after their surgery for 6 weeks.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: No Precautions
Description: For the non-precautions group, there will be no mention of precautions by any providers before, during, and after surgery. No equipment will be given, but a list of self-care equipment will be available for 'comfort' purposes. Patients will be instructed to avoid bathing for 4 weeks. All groups will have instructions to use a walking aid and a toilet seat if needed, to weight-bear as tolerated, and to avoid driving for 3 weeks.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: No Precautions
Description: For the non-precautions group, there will be no mention of precautions by any providers before, during, and after surgery. No equipment will be given, but a list of self-care equipment will be available for 'comfort' purposes. Patients will be instructed to avoid bathing for 4 weeks. All groups will have instructions to use a walking aid and a toilet seat if needed, to weight-bear as tolerated, and to avoid driving for 3 weeks.
Study: NCT05086705

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EMBr Wave
Description: Use EMBr Wave
Study: NCT01815268

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: SD Vaccine
Description: Nursing home residents are allocated to receive standard-dose vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Free Vaccine
Description: Nursing home facilities are provided free standard-dose vaccine for their staff.
Study: NCT05086705

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EMBr Wave
Description: Use EMBr Wave

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT01815268

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Free Vaccine
Description: Nursing home facilities are provided free standard-dose vaccine for their staff.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Nursing home staff will have access to influenza vaccine, per standard of care. No free vaccine provided as part of study.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Nursing home staff will have access to influenza vaccine, per standard of care. No free vaccine provided as part of study.
Study: NCT02943603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFLOFOX6 + pembrolizumab
Description: the combination of mFOLFOX6 + pembrolizumab is the single intervention even though the is dosed differently.
Study: NCT03200938

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: formocresol and zinc oxide.
Description: Removal of the coronary pulp from primary molar teeth, use of formocresol and zinc oxide

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PBS CIMMO cement.
Description: Removal of the coronary pulp from primary molar teeth, use of PBS cement
Study: NCT04111081

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auricular pressure
Description: Select related auricular points: Shenmen(TF4), sympathetic(AH6a), rectum(HX2), anus(HX5), stomach(CO4), subcortical(AT4). The auricle skin of the patient was disinfected 24 hours after the operation, and wanghuoxing seed will be used for stimulation. Ask patients press every two hours for one minute at each point. When the pain is severe, do pressure compressions at each point for 2 minutes once hour.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Shame auricular pressure
Description: Select unrelated auricular points: eye(LO5), occipital(AT3), tonsil(LO7,8,9), lower auricular root(R3), dorsum auricular kidney(P5) and dorsum auricular lung(P2). The auricle skin of the patient was disinfected 24 hours after the operation, and wanghuoxing seed will be used for stimulation. Ask patients press every two hours for one minute at each point. When the pain is severe, do pressure compressions at each point for 2 minutes once hour.
Study: NCT02451800

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: in-class yoga
Description: In-person yoga classes that meet for 3x/week for 3 months. Each class is 1 hour.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: yoga by DVD
Description: Individuals are asked to follow a 1-hour DVD on yoga 3x/week for 3 months.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: stretching by DVD
Description: Individuals are asked to follow a 1-hour DVD on stretching exercises 3x/week for 3 months.
Study: NCT02148250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: U-500 insulin, 100 syringe units
Description: Subjects are randomized to receive 100 syringe units of U-500 insulin. Subjects will receive opposite treatment after 4-8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: U-500 insulin, 100 syringe units
Description: Subjects are randomized to receive 100 syringe units of U-500 insulin. Subjects will receive opposite treatment after 4-8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: U-500 insulin, 200 syringe units
Description: Subjects are randomized to receive 200 syringe units of U-500 insulin. Subjects will receive opposite treatment after 4-8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: U-500 insulin, 200 syringe units
Description: Subjects are randomized to receive 200 syringe units of U-500 insulin. Subjects will receive opposite treatment after 4-8 weeks.
Study: NCT03197792

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: All patients
Description: TEE is performed before cardiopulmonary bypass (before the opening of the pericardium, if possible) and immediately after weaning from cardiopulmonary bypass and optimization of the hemodynamic status by the attending anesthesiologist. A detailed ultrasound examination including portal vein pulsatility, splenic vein pulsatility, right and left ventricular global longitudinal strain and right and left systolic and diastolic function is recorded. A measure of portal vein pulsatility using TTE is also recorded before the onset of general anesthesia and on the morning of the 7th postoperative day.~On the 7th postoperative day, the investigators will evaluate for the presence of the primary outcome, POD + death.
Study: NCT00426504

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Helical Tomotherapy Intensity Modulated Radiotherapy (HT-IMRT) with the intend of delivering radical radiotherapy to a dose of 66-70 Gy to involved areas and at least 50 Gy to un-involved sites to be treated prophylactically.
Study: NCT03223363

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 2D and 3D ultrasonography
Description: All of the examinations are performed with the same transabdominal ultrasonic transducer (RAB 2-5-D) on the same E8 (GE Medical Systems, Milwaukee, WI, USA) ultrasonic machine experienced operators. 2D ultrasonic measurements includes 5 standard fetal biometry parameters, and after routine 2D ultrasonography, the acquisition of 3D measurements are performed.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 2D and 3D ultrasonography
Description: All of the examinations are performed with the same transabdominal ultrasonic transducer (RAB 2-5-D) on the same E8 (GE Medical Systems, Milwaukee, WI, USA) ultrasonic machine experienced operators. 2D ultrasonic measurements includes 5 standard fetal biometry parameters, and after routine 2D ultrasonography, the acquisition of 3D measurements are performed.
Study: NCT02186119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abicipar pegol
Description: Abicipar pegol administered to the study eye by intravitreal injection at the visits noted per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abicipar pegol
Description: Abicipar pegol administered to the study eye by intravitreal injection at the visits noted per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abicipar pegol
Description: Abicipar pegol administered to the study eye by intravitreal injection at the visits noted per protocol.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab
Description: Ranibizumab (Lucentis®) administered to the study eye by intravitreal injection every 4 weeks from day 1 through week 24.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sham procedure
Description: Sham procedure to the study eye at the visits noted per protocol.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sham procedure
Description: Sham procedure to the study eye at the visits noted per protocol.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sham procedure
Description: Sham procedure to the study eye at the visits noted per protocol.
Study: NCT02485470

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MPACT
Description: Maintaining Physical Activity during Cancer Treatment
Study: NCT01876719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR08

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR08

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR08

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02592434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550 (tofacitinib)
Description: During the open label run in phase, all subjects will receive active tofacitinib oral tablets or oral solution twice daily (BID) orally, at a dosage based on the subject's body weight as specified below.~During the double blind, placebo controlled phase, subjects will receive either active tofacitinib oral tablets/oral solution or matching placebo oral tablets/oral solution, twice daily (BID), at a dosage specified below.~Body Weight (Dosage in tablet \[BID\] or solution \[BID\]):~5\<7kg (2mg or 2mL); 7\<10kg(2.5mg or 2. mL); 10 \<15kg (3mg or 3mL); 15\<25kg (3.5mg or 3.5mL); 25\<40kg (4mg or 4mL); 40kg (5 mg or 5 ml).~Oral solution (1 mg/mL) is used for subjects \<40 kg. Oral tablets (5 mg) are used for subjects \>=40 kg.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching placebo tablet or solution for tofacitinib
Study: NCT01725087

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose GRT6005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medium Dose GRT6005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose GRT6005

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tapentadol
Study: NCT02509754

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation catheter ablation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rate control
Description: Composite of optimal medical therapy and device implantation
Study: NCT01747616

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chitosan-N-acetylcysteine eye drops (concentration of 0.1%)
Description: 1 drop of the medical device in 1 randomly chosen eye

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chitosan-N-acetylcysteine eye drops (concentration of 0.1%)
Description: 1 drop of the medical device in 1 randomly chosen eye
Study: NCT02500017

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: 5mg rapid release melatonin capsule

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo capsule
Study: NCT04352842

Intervention type: OTHER
Intervention: Echocardiography
Description: An expert with 17-year professional experience performed all the echocardiography examinations using a GE LOGIQTM e portable color ultrasound diagnostic machine (GE Healthcare, WI, USA) that was specially used in the contaminated area. Two-dimensional and Doppler echocardiographic measurements were conducted following the recommendations of the American Society of Echocardiography

Intervention type: OTHER
Intervention: Echocardiography
Description: An expert with 17-year professional experience performed all the echocardiography examinations using a GE LOGIQTM e portable color ultrasound diagnostic machine (GE Healthcare, WI, USA) that was specially used in the contaminated area. Two-dimensional and Doppler echocardiographic measurements were conducted following the recommendations of the American Society of Echocardiography